International Journal of Hematology

, Volume 93, Issue 6, pp 745–749

Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis

  • Yukio Kobayashi
  • Hisashi Sakamaki
  • Shin Fujisawa
  • Kiyoshi Ando
  • Kazuhito Yamamoto
  • Masaya Okada
  • Kenichi Ishizawa
  • Tadashi Nagai
  • Syuichi Miyawaki
  • Toshiko Motoji
  • Noriko Usui
  • Shinsuke Iida
  • Masafumi Taniwaki
  • Nobuhiko Uoshima
  • Taku Seriu
  • Ryuzo Ohno
Original Article

DOI: 10.1007/s12185-011-0864-1

Cite this article as:
Kobayashi, Y., Sakamaki, H., Fujisawa, S. et al. Int J Hematol (2011) 93: 745. doi:10.1007/s12185-011-0864-1
  • 231 Downloads

Abstract

The aim of this retrospective study was to evaluate the toxicity profiles of dasatinib in patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) or acute lymphatic leukemia (ALL) who were intolerant to imatinib, and who had been enrolled in our previous clinical trials to evaluate efficacy of dasatinib in patients resistant or tolerant to imatinib therapy. Twenty-four patients with CML and four with ALL were enrolled in the clinical studies to evaluate the efficacy according to the eligibility criteria related to intolerance to imatinib therapy. The toxicities reported during imatinib therapy were non-hematological toxicities in 23 patients and hematological toxicities in six patients. Patients were administered dasatinib 50–70 mg BID or 100 mg QD. Cross intolerance was observed in four patients who showed hematological toxicity after dasatinib treatment. However, it was possible to successfully continue therapy with only temporary interruption. No cross intolerance in non-hematological toxicity was found with the exception of one patient who showed cross intolerance, which did not result in treatment interruption. Dasatinib can be safely administered to imatinib-intolerant CML or Ph-positive ALL patients.

Keywords

Dasatinib Cross intolerance CML ALL 

Copyright information

© The Japanese Society of Hematology 2011

Authors and Affiliations

  • Yukio Kobayashi
    • 1
  • Hisashi Sakamaki
    • 2
  • Shin Fujisawa
    • 3
  • Kiyoshi Ando
    • 4
  • Kazuhito Yamamoto
    • 5
  • Masaya Okada
    • 6
  • Kenichi Ishizawa
    • 7
  • Tadashi Nagai
    • 8
  • Syuichi Miyawaki
    • 9
    • 10
  • Toshiko Motoji
    • 11
  • Noriko Usui
    • 12
  • Shinsuke Iida
    • 13
  • Masafumi Taniwaki
    • 14
  • Nobuhiko Uoshima
    • 15
  • Taku Seriu
    • 16
  • Ryuzo Ohno
    • 17
  1. 1.Hematology DivisionNational Cancer Center HospitalTokyoJapan
  2. 2.Hematology Division, Tokyo Metropolitan Cancer and Infectious diseases CenterKomagome HospitalTokyoJapan
  3. 3.Department of HematologyYokohama City University Medical CenterYokohamaJapan
  4. 4.Department of Hematology and OncologyTokai University School of MedicineIseharaJapan
  5. 5.Hematology and Cell Therapy DivisionAichi Cancer Center HospitalNagoyaJapan
  6. 6.Division of Hematology, Department of Internal MedicineHyogo College of MedicineNishinomiyaJapan
  7. 7.Department of Hematology and RheumatologyTohoku University HospitalSendaiJapan
  8. 8.Division of HematologyJichi Medical UniversityShimotsukeJapan
  9. 9.Leukemia Research CenterSaiseikai Maebashi HospitalMaebashiJapan
  10. 10.Division of HematologyTokyo Metropolitan Ohtsuka HospitalTokyoJapan
  11. 11.Department of HematologyTokyo Women’s Medical UniversityTokyoJapan
  12. 12.Division of Clinical Oncology and Hematology, Department of Internal MedicineThe Jikei University School of MedicineTokyoJapan
  13. 13.Department of Medical Oncology and ImmunologyNagoya City University Graduate School of Medical SciencesNagoyaJapan
  14. 14.Division of Hematology and Oncology, Department of MedicineKyoto Prefectural University of MedicineKyotoJapan
  15. 15.Department of Internal MedicineMatsushita Memorial HospitalOsakaJapan
  16. 16.Bristol-Myers K.KTokyoJapan
  17. 17.Aichi Cancer Center HospitalNagoyaJapan

Personalised recommendations